Description: The drug rituximab reduces disease activity in people with the relapsing-remitting form of multiple sclerosis (MS), according to two new studies. Rituximab selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on the cell surface. It's the first drug designed to target B-cells and may offer a new treatment for relapsing-remitting MS.